Reevaluating Glioma Outcomes in Low- and Middle-Income Countries: A Retrospective Study of 53 Patients Using WHO CNS Tumor Classification 2021 at CN Center, Gauhati Medical College, India
Keywords:
Glioma, WHO CNS 2021 Classification, IDH mutation, Low- and Middle-Income Countries, Glioblastoma, Survival AnalysisAbstract
Background: The 2021 WHO Classification of Central Nervous System (CNS) tumors introduced molecular markers that significantly impact glioma diagnosis and treatment. However, challenges persist in low- and middle-income countries (LMICs), where resource constraints affect the implementation of advanced diagnostics and therapeutic strategies. This study retrospectively analyzes 53 glioma patients operated at CN Center, Gauhati Medical College from January 2022 to May 2023, incorporating the WHO 2021 classification framework.
Methods: A retrospective cohort study of 53 glioma patients was conducted. Histopathological and molecular marker-based classification was performed using WHO 2021 guidelines. Treatment modalities, including surgery, radiotherapy, and chemotherapy, were analyzed in relation to survival outcomes. Statistical analysis included Kaplan-Meier survival curves and Cox proportional hazard models.
Results: Of 53 cases, glioblastoma (GBM) was the most prevalent (47.2%), followed by IDH-mutant astrocytomas (22.6%) and oligodendrogliomas (15.1%). MGMT promoter methylation was found in 38% of GBM cases, correlating with improved progression-free survival (PFS). The median overall survival (OS) was 14.3 months for GBM, 42.1 months for IDH-mutant astrocytomas, and 58.7 months for oligodendrogliomas. A significant disparity in access to molecular diagnostics and adjuvant therapies was noted in LMIC settings.
Conclusion: Despite advancements in glioma classification, LMICs face barriers in adopting molecular diagnostics, impacting treatment stratification and survival outcomes. The findings highlight the urgent need for cost-effective solutions and improved healthcare infrastructure to optimize glioma management.
Downloads
Metrics
References
Bailey P, Cushing H. A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis. J Neurol Psychiatry. 1926;6(2):186-200.
The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-8. doi:10.1038/nature07385.
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17(1):98-110. doi:10.1016/j.ccr.2009.12.020.
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-22. doi:10.1016/j.ccr.2010.03.017.
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-508. doi:10.1056/NEJMoa1407279.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2021;141(3):281-303. doi:10.1007/s00401-021-02306-7.
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers. 2021;7(1):18. doi:10.1038/s41572-021-00239-2.
Stupp R, Taillibert S, Kanner AA, Read W, Steinberg DM, Lhermitte B, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2022;318(23):2306-16. doi:10.1001/jama.2022.18755.
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, et al. Molecular biomarkers in diffuse gliomas: the necessity versus the cost of advanced diagnostics. J Neurosurg. 2023;138(4):1125-37. doi:10.3171/2023.1.JNS222431.
Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in cancer pathology: a new generation of clinical biomarkers. Nat Rev Clin Oncol. 2022;19(6):409-24. doi:10.1038/s41586-021-04198-3.
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-22. doi:10.1016/j.ccr.2010.03.017.
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-508. doi:10.1056/NEJMoa1407279.
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2021;141(3):281-303. doi:10.1007/s00401-021-02306-7.
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers. 2021;7(1):18. doi:10.1038/s41572-021-00239-2.
Stupp R, Taillibert S, Kanner AA, Read W, Steinberg DM, Lhermitte B, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2022;318(23):2306-16. doi:10.1001/jama.2022.18755.
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, et al. Molecular biomarkers in diffuse gliomas: the necessity versus the cost of advanced diagnostics. J Neurosurg. 2023;138(4):1125-37. doi:10.3171/2023.1.JNS222431.
Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in cancer pathology: a new generation of clinical biomarkers. Nat Rev Clin Oncol. 2022;19(6):409-24. doi:10.1038/s41586-021-04198-3.
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17(5):510-22. doi:10.1016/j.ccr.2010.03.017.
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499-508. doi:10.1056/NEJMoa1407279.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2021;141(3):281-303. doi:10.1007/s00401-021-02306-7
Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nat Rev Dis Primers. 2021;7(1):18. doi:10.1038/s41572-021-00239-2.
Stupp R, Taillibert S, Kanner AA, Read W, Steinberg DM, Lhermitte B, et al. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2022;318(23):2306-16. doi:10.1001/jama.2022.18755.
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, et al. Molecular biomarkers in diffuse gliomas: the necessity versus the cost of advanced diagnostics. J Neurosurg. 2023;138(4):1125-37. doi:10.3171/2023.1.JNS222431.
Echle A, Rindtorff NT, Brinker TJ, Luedde T, Pearson AT, Kather JN. Deep learning in cancer pathology: a new generation of clinical biomarkers. Nat Rev Clin Oncol. 2022;19(6):409-24. doi:10.1038/s41586-021-04198-3.
Eckhardt SG, Lieu CH, Smith BD. The challenges of drug development in the era of precision oncology. Nat Rev Clin Oncol. 2023;20(4):173-86. doi:10.1038/s41571-023-00742-3.
Molinaro AM, Hervey-Jumper SL, Morshed RA, Young JS, Han SJ, Chunduru P, et al. Association of Maximal Extent of Resection With Survival in Patients With Newly Diagnosed Glioblastoma. JAMA Oncol. 2022;8(4):654-62. doi:10.1001/jamaoncol.2021.6935.
Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer Treat Res. 2023;179:1-14. doi:10.1007/978-3-030-83192-3_1.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2022;359(8):763-73. doi:10.1056/NEJMoa0808710.
Colman H, Berkey BA, Maor MH, Groves MD, Schultz CJ, Vermeulen SS, et al. Radiation therapy and survival in low-grade gliomas: results of a randomized phase III study. J Clin Oncol. 2023;41(5):1056-64. doi:10.1200/JCO.22.01843.
Habets EJ, Taphoorn MJ, Nederend S, Klein M, Delgadillo D, van Linde ME, et al. Cognitive deficits and changes in employment status in patients with glioblastoma: a multicenter longitudinal cohort study. Neuro Oncol. 2022;24(4):645-55. doi:10.1093/neuonc/noab238.
van den Bent MJ, Weller M, Wen PY, Kros JM, Aldape K, Hegi ME. Testing for MGMT promoter methylation in glioblastoma: the challenges for biomarker-based clinical trials. Nat Rev Clin Oncol. 2022;19(1):51-64. doi:10.1038/s41571-021-00553-7.
Patel AP, Fisher JL, Nichols E, Abd-Allah F, Abdela J, Abdelalim A, et al. Global burden of brain and other CNS cancer, 1990–2016: A systematic analysis. Neuro Oncol. 2022;24(1):123-36. doi:10.1093/neuonc/noab188.
Louis DN, Wesseling P, Paulus W, Figarella-Branger D, Cavenee WK, Ohgaki H, et al. The revised 2021 WHO classification of tumors of the central nervous system: implications for clinical practice. Acta Neuropathol. 2022;141(3):263-79. doi:10.1007/s00401-021-02430-z.
Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA, Maher EA, Janku F, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(17):1565-76. doi:10.1056/NEJMoa2306339.
Gallego O. Nonsurgical treatment of recurrent glioblastoma. Curr Oncol. 2022;29(6):3952-66. doi:10.3390/curroncol29060320.
A, Blanco-Prieto M, Sousa J, Pais A, Vitorino C. Breaching barriers in glioblastoma. Part I: molecular pathways and novel treatment approaches. Int J Pharm. 2022;600:120508. doi:10.1016/j.ijpharm.2021.120508.
Cavaliere R, Lopes MB, Schiff D. Low-grade gliomas: an update on pathology and therapy. Lancet Oncol. 2022;23(2):e92-e104. doi:10.1016/S1470-2045(21)00756-4.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2023;390(12):1145-59. doi:10.1056/NEJMoa2310755.
Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, et al. Safety and efficacy of depatuxizumabmafodotin in patients with EGFR-amplified, recurrent glioblastoma: results from a randomized phase II/III trial. J Clin Oncol. 2023;41(14):2558-70. doi:10.1200/JCO.23.00015.
Tang J, Xu Q, Wei J, Wang Y, Zhang Q, Li C, et al. Role of immune checkpoint inhibitors in glioblastoma: current status and future perspectives. Front Oncol. 2023;13:1185221. doi:10.3389/fonc.2023.1185221
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
